It is known that the selective ER modulator tamoxifen, which is used to block ER activity for breast cancer treatment, is paradoxically an ER agonist in the normal endometrium and endometrial cancer cells, including the Ishikawa cell line16,17,36,37. This evidence concerns the gene ESR1 and breast carcinoma.